Sensus Healthcare (NASDAQ:SRTS) Price Target Raised to $12.00

Sensus Healthcare (NASDAQ:SRTS) had its price target increased by HC Wainwright from $11.00 to $12.00 in a research report released on Monday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Sensus Healthcare’s Q1 2025 earnings at $0.11 EPS, Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.10 EPS, Q4 2025 earnings at $0.16 EPS and FY2025 earnings at $0.44 EPS.

Several other equities analysts have also issued reports on the stock. Lake Street Capital initiated coverage on shares of Sensus Healthcare in a report on Friday, January 31st. They issued a “buy” rating and a $18.00 target price on the stock. Maxim Group boosted their target price on shares of Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a report on Friday, November 15th.

Sensus Healthcare Stock Down 4.7 %

SRTS stock opened at $5.65 on Monday. The firm has a market cap of $92.60 million, a price-to-earnings ratio of 14.13 and a beta of 1.24. Sensus Healthcare has a 12-month low of $2.91 and a 12-month high of $9.33. The company’s fifty day simple moving average is $7.28 and its 200 day simple moving average is $6.88.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. Research analysts expect that Sensus Healthcare will post 0.71 earnings per share for the current year.

Hedge Funds Weigh In On Sensus Healthcare

Institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its holdings in shares of Sensus Healthcare by 8.5% during the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after purchasing an additional 11,525 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Sensus Healthcare by 128.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock worth $888,000 after acquiring an additional 93,511 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Sensus Healthcare in the 2nd quarter worth about $156,000. XTX Topco Ltd raised its holdings in shares of Sensus Healthcare by 76.0% in the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock worth $183,000 after acquiring an additional 13,619 shares during the last quarter. Finally, Truvestments Capital LLC acquired a new stake in shares of Sensus Healthcare in the 3rd quarter worth about $32,000. Institutional investors and hedge funds own 25.30% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.